Accent Therapeutics has halted work on a solid tumor drug due to adverse events in a phase 1/2 study. | Accent Therapeutics has halted work on a solid tumor drug due to adverse events in a phase 1/2 ...

The American Academy of Pediatrics has revised its policy statement on facility-based requirements for pediatric anesthesia.  The AAP last updated the policy statement in 2015. The new guidance ...

Regulatory officials have granted Molbreevi priority review and assigned a goal date of Aug. 22, 2026. If approved, Molbreevi will be priced between $400,000 and $500,000 per year.

SAN FRANCISCO, CA—In the 3-and-a-half years after the Watchman device (Boston Scientific) was approved for left atrial appendage (LAA) occlusion in high-risk patients with atrial fibrillation, ...

Health care workers face adverse events daily. These events include secondary trauma, occupational trauma, unexpected death or injury, moral injury, medical error and ...

A new analysis from Frost & Sullivan takes a closer look at 30 adverse patient safety events in healthcare and how much they are costing the system. In 2016, such occurrences cost the U.S. and ...

For decades, an unassuming government vaccine safety surveillance system has done its job, quickly flagging possible side effects and allowing scientists and regulators to investigate further. But for ...

Immunotherapy enhances a patient’s immune system to fight disease and has recently been a source of promising new cancer treatments. Among the many immunotherapeutic strategies, immune checkpoint ...